Monday, November 9, 2015
The Pulse on Global Trials by Matthew Howes
Accelerating the introduction of new therapies is a dynamic topic throughout the global healthcare community. The FDA and EMA have developed fast-track review-and-approval processes for novel agents in rare diseases. Advocacy organizations maintain media pressure on government and businesses to improve care of elderly and underserved populations. And healthcare companies are in merger frenzy as small biotech companies with breakthrough discoveries pop up before being acquired just as quickly by big pharma.